A Study to Assess Safety & Effectiveness of Tovinontrine in Chronic Heart Failure With Reduced Ejection Fraction (Cycle-1-REF)
A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 557 participants.
Also called NCT06215911
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase
- Phase 2
- Enrolled
- 557 participants
- Registry
-
NCT06215911 -
2023-508736-62
-
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Countries
- United States, Australia, Belgium, Bulgaria, Canada, Czechia, Georgia, Germany, Hungary, Italy, Latvia, Lithuania, Netherlands, New Zealand, Poland, Slovakia, Spain, Taiwan, United Kingdom
- Registry status
- Completed
Technical summary
Registry record NCT06215911. Randomized; quadruple masking; primary purpose treatment. Start 2024-02-13 (actual); primary completion 2025-10-10 (actual). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- A Study to Assess Safety & Effectiveness of Tovinontrine in Chronic Heart Failure With Reduced Ejection Fraction (Cycle-1-REF)
- Acronym
- Cycle-1-REF
- Condition
- Heart Failure
- Condition
- Cardiovascular Diseases
- Condition
- Heart Diseases
- Intervention (Drug)
- Tovinontrine (CRD-750)
- Intervention (Drug)
- Placebo
- Lead sponsor
- Cardurion Pharmaceuticals, Inc.
Record details
- Record id
cardio:ct-nct06215911- Content hash
b1a56c10b6bd7fa6bb06d4709441181c7f92d48250ed174cc87123721d2a178c